Evidence map›Paper›PMID 26688733›Full record

ArticleBMJ open diabetes research & care2015

The effect of metformin on cardiovascular risk profile in patients without diabetes presenting with acute myocardial infarction: data from the Glycometabolic Intervention as adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) trial.

Chris P H Lexis, Anouk N A van der Horst-Schrivers, Erik Lipsic, Mattia A E Valente, Anneke C Muller Kobold, Rudolf A de Boer, Dirk J van Veldhuisen, Pim van der Harst, Iwan C C van der Horst

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open diabetes research & care, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01217307. Cited by 17 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01217307 phase2 / phase3completed

Metabolic Modulation With Metformin to Reduce Heart Failure After Acute Myocardial Infarction: Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III): a Randomized Controlled Trial.

Ran2011Enrolled380Registered outcomes7Posted comparisons0ConditionsCoronary Artery Disease, Diabetes, Heart Failure, ST Elevation Myocardial Infarction (STEMI)ArmsMetformin, Placebo
Open the trial in the graph
NCT04826692 phase3completednot on this mapstarted 2022, after this paper: background citation

"Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"

TypeinterventionalSponsorInstituto de Investigacion Sanitaria La FeRan2022 to 2025Enrolled60ConditionsHuntington DiseaseArmsMetformin, Placebo
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT.Clinical research in cardiology : official journal of the German Cardiac Society · 2017
    Trial
  5. Article
  6. Metformin Beyond Glycemic Control: Cardiovascular Protection and Diabetes Prevention.Journal of cardiovascular development and disease · 2026
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Metformin: A Novel Weapon Against Inflammation.Frontiers in pharmacology · 2021
    Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Chris P H LexisDepartment of Cardiology , University of Groningen, University Medical Center Groningen , Groningen , The Netherlands.
Anouk N A van der Horst-SchriversDepartment of Endocrinology , University of Groningen, University Medical Center Groningen , Groningen , The Netherlands.
Erik LipsicDepartment of Cardiology , University of Groningen, University Medical Center Groningen , Groningen , The Netherlands.
Mattia A E ValenteDepartment of Cardiology , University of Groningen, University Medical Center Groningen , Groningen , The Netherlands.
Anneke C Muller KoboldDepartment of Laboratory Medicine , University of Groningen, University Medical Center Groningen , Groningen , The Netherlands.
Rudolf A de BoerDepartment of Cardiology , University of Groningen, University Medical Center Groningen , Groningen , The Netherlands.
Dirk J van VeldhuisenDepartment of Cardiology , University of Groningen, University Medical Center Groningen , Groningen , The Netherlands.
Pim van der HarstDepartment of Cardiology , University of Groningen, University Medical Center Groningen , Groningen , The Netherlands.
Iwan C C van der HorstDepartment of Critical Care , University of Groningen, University Medical Center Groningen , Groningen , The Netherlands.
University of Groningen · NLUniversity Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIn patients with diabetes mellitus, metformin treatment is associated with reduced mortality and attenuation of cardiovascular risk. As a subanalysis of the Glycometabolic Intervention as adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) study, we evaluated whether metformin treatment in patients with ST-segment elevation myocardial infarction (STEMI) without diabetes improves the cardiovascular risk profile.

methodsA total of 379 patients, without known diabetes, presenting with STEMI were randomly allocated to receive metformin 500 mg twice daily or placebo for 4 months.

resultsAfter 4 months, the cardiovascular risk profile of patients receiving metformin (n=172) was improved compared with placebo (n=174); glycated hemoglobin (5.83% (95% CI 5.79% to 5.87%) vs 5.89% (95% CI 5.85% to 5.92%); 40.2 mmol/mol (95% CI 39.8 to 40.6) vs 40.9 mmol/mol (40.4 to 41.2), p=0.049); total cholesterol (3.85 mmol/L (95% CI 3.73 to 3.97) vs 4.02 mmol/L (95% CI 3.90 to 4.14), p=0.045); low-density lipoprotein cholesterol (2.10 mmol/L (95% CI 1.99 to 2.20) vs 2.3 mmol/L (95% CI 2.20 to 2.40), p=0.007); body weight (83.8 kg (95% CI 83.0 to 84.7) vs 85.2 kg (95% CI 84.4 to 86.1), p=0.024); body mass index (26.8 kg/m(2) (95% CI 26.5 to 27.0) vs 27.2 kg/m(2) (95% CI 27.0 to 27.5), p=0.014). Levels of fasting glucose, postchallenge glucose, insulin, high-density lipoprotein cholesterol, and blood pressure were similar in both groups.

conclusionsAmong patients with STEMI without diabetes, treatment with metformin for 4 months resulted in a modest improvement of the cardiovascular risk profile compared with placebo. TRIAL REGISTER NUMBER: NCT01217307.

Indexed as

Cardiac FunctionCardiovascular Disease RiskCardiovascular Risk FactorsMetformin

Identifiers

PMID26688733
PMCPMC4679814
OpenAlexW2197331808

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.